Share Prices & Company Research

Stockbroking

Circassia Pharmaceuticals

Current Price 0.00p Bid 0.00p Ask 0.00p Change 0.00%
Last Updated: 09/05/2024 14:28. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Niox Group is a specialty biopharmaceutical company focused on the development and commercialisation of a range of immunotherapy product candidates for the treatment of allergy.

Financial Highlights Year Ended 31/12/2023

Revenue
£36.80m
Operating Profit/Loss
£4.60m
Dividend yield (%)
n/a
Total dividend for year
n/ap
Dividend cover
1.11
P/E Ratio
n/a
More Financials

Key Personnel

Mr Michael R D Roller
Chief Financial Officer and Senior Vice President
Mr Ian Johnson
Executive Chairman
Mr Jonathan Emms
Executive Director
Mr Jo Le Couilliard
Non-Executive Chairman
Mr Garry Watts
Non-Executive Director
Mr Nicholas Mills
Non-Executive Director
Mr Sharon Curran
Non-Executive Director

Stock Details

EPIC
CIRL
ISIN
GB00BJVD3B28
Shares in Issue
284.89m
Market cap
£0.00m

Analyst Views (2)

Strong Buy
 
50.00%
Buy
 
50.00%
Hold
 
0%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
0.00p
Bid Price
0.00p
Ask Price
0.00p
Volume
0
Change Today
0.00p
% Change Today
0.00%
Open
0.00p
Previous Close
0.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
0.00p
52 Week Low
0.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

Income Statement

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Continuing Operations
Revenue
36.80
31.30
Operating Profit/Loss
4.60
1.80
Net Interest
0.60
n/a
Pre-Tax Profit
4.10
10.50
Profit After Tax from continuing operations
9.50
14.10
Discontinued Operations
Profit After Tax
1.20
2.00
Profit/Loss for the Year
10.70
16.10
Attributable to:
Equity Holders of Parent Company
10.70
16.10
Minority Interests
n/a
n/a
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2023
31 Dec 2022
Basic
2.26p
3.36p
Diluted
2.11p
3.19p
Adjusted
4.16p
3.21p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
1.40
1.10
Intangible Assets
32.80
37.10
Investment Properties
n/a
n/a
Investments
n/a
n/a
Other Financial Assets
n/a
n/a
Other Non-Current Assets
23.80
28.90
Current Assets
Inventories
4.80
4.10
Trade & Other Receivables
8.80
7.90
Cash at Bank & In Hand
19.90
19.40
Current Asset Investments
n/a
n/a
Other Current Assets
n/a
n/a
Other Assets
n/a
n/a
Total Assets
91.50
98.50

Liabilities

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Current Liabilities
Borrowings
0.60
0.60
Other Current Liabilities
6.60
8.60
Total Current Liabilities
7.20
9.20
Non-Current Liabilities
Borrowings
0.50
0.40
Provisions
n/a
7.00
Other Non-Current Liabilities
n/a
n/a
Total Non-Current Liabilities
0.50
7.40
Other Liabilities
n/a
n/a
Total Liabilities
7.70
16.60

Net Assets

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Net Assets
83.80
81.90

Capital & Reserves

Year End Date
31 Dec 2023
31 Dec 2022
 
£ (M)
£ (M)
Share Capital
0.30
0.30
Share Premium Account
0.10
640.30
Other Reserves
18.20
15.70
Retained Earnings
65.20
-574.40
Shareholders Funds
83.80
81.90
Minority Interests/Other Equity
n/a
n/a
Total Equity
83.80
81.90

Dividend History

Dividend Metrics

Year End Date
31 Dec 2023
31 Dec 2022
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
1.11
n/a


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.